Edinburgh Research Explorer

Promoting remyelination in multiple sclerosis-recent advances

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Rights statement: Copyright © The Author(s) 2013 Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

    Final published version, 438 KB, PDF document

http://link.springer.com/article/10.1007%2Fs40265-013-0146-8
Original languageEnglish
Pages (from-to)2017-29
Number of pages13
JournalDrugs
Volume73
Issue number18
DOIs
Publication statusPublished - Dec 2013

Abstract

We review the current state of knowledge of remyelination in multiple sclerosis (MS), concentrating on advances in the understanding of the pathology and the regenerative response, and we summarise progress on the development of new therapies to enhance remyelination aimed at reducing progressive accumulation of disability in MS. We discuss key target pathways identified in experimental models, as although most identified targets have not yet progressed to the stage of being tested in human clinical trials, they may provide treatment strategies for demyelinating diseases in the future. Finally, we discuss some of the problems associated with testing this class of drugs, where they might fit into the therapeutic arsenal and the gaps in our knowledge.

Download statistics

No data available

ID: 11823192